GSK plc (LON:GSK) Insider Emma Walmsley Sells 38,459 Shares of Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 38,459 shares of GSK stock in a transaction on Monday, February 17th. The shares were sold at an average price of GBX 1,418 ($17.92), for a total value of £545,348.62 ($689,006.47).

Emma Walmsley also recently made the following trade(s):

• On Monday, February 10th, Emma Walmsley sold 120,653 shares of GSK stock. The shares were sold at an average price of GBX 1,453 ($18.36), for a total value of £1,753,088.09 ($2,214,893.35).

GSK Price Performance

GSK opened at GBX 1,429 ($18.05) on Friday. The company’s 50-day simple moving average is GBX 1,377.06 and its two-hundred day simple moving average is GBX 1,450.64. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a market capitalization of £57.99 billion, a P/E ratio of 23.08, a P/E/G ratio of 1.24 and a beta of 0.31. GSK plc has a 52-week low of GBX 1,282.50 ($16.20) and a 52-week high of GBX 1,823.50 ($23.04).

GSK (LON:GSK) last issued its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts predict that GSK plc will post 175.980975 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on GSK. Berenberg Bank cut their price objective on shares of GSK from GBX 1,820 ($22.99) to GBX 1,600 ($20.21) and set a “buy” rating on the stock in a research report on Friday, November 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.82).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.